New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
13:31 EDTC, SHPGShire selects Citi as adviser to prepare for takeover offers, Reuters reports
News For SHPG;C From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 13, 2015
12:05 EDTCCiti's Bird to replace Medina-Mora, run global consumer bank, Bloomberg says
Subscribe for More Information
07:20 EDTSHPGShire price target raised to $288 from $267 at JPMorgan
JPMorgan raised its price target for Shire to $288 after lifting its estimates for Lifitegrast in dry eye following the FDA's Priority Review designation. The firm believes the FDA is very likely to approve the application in October of this year, without waiting for the third Phase III study late 2015. It upped its 2020 Lifitegrast forecasts by $600M to $900M and reiterates an Overweight rating on Shire.
April 10, 2015
06:11 EDTCCiti's head of franchise risk and strategy to retire, WSJ reports
Citigroup's head of franchise risk and strategy, Brian Leach, will retire as of April 30, The Wall Street Journal reports, citing memos from Leach and Citigroup CEO Michael Corbat. Mark Carawan, the bank's audit head, John Davidson, the bank's compliance head, and Chef Risk Offiver Brad Hu, will now report directly to Corbat. Reference Link
April 9, 2015
19:39 EDTCCiti weighs return to Cuba, Reuters says
Subscribe for More Information
17:08 EDTCCiti head of Franchise Risk and Strategy, Brian Leach, to retire on April 30
Brian Leach, Citiís Head of Franchise Risk and Strategy, has submitted a notice of retirement to Citi. The effective date of the retirement is April 30.
13:27 EDTSHPGShire announces FDA Priority Review designation for lifitegrast
Subscribe for More Information
10:48 EDTSHPGDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
07:35 EDTCFitch Ratings to hold a webcast
Subscribe for More Information
06:57 EDTCCitibank sued by Argentina over deal with creditors, Reuters reports
Citibank Argentina has been sued by Argentina over what it says is an illegal deal with a group of creditors in conflict with the government over unpaid debt, Reuters reports. Citigroup says it is "disappointed" by Argentina's legal actions and has denied violating laws. Reference Link
05:27 EDTSHPGShire reports results from three placebo-controlled Phase 2 studies of SHP625
Subscribe for More Information
April 8, 2015
16:01 EDTCActionable Options for Wednesday, April, 8
Subscribe for More Information
April 7, 2015
16:00 EDTCOptions Update; April 7, 2015
Subscribe for More Information
11:02 EDTCAmerican Express slips after analyst, columnist highlight challenges
Subscribe for More Information
10:10 EDTSHPGJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
08:10 EDTSHPGShire shares pricing in worst case scenario for patents, says Citigroup
Subscribe for More Information
07:16 EDTCRising competition may make AmEx targets hard to achieve, WSJ says
Though American Express recently reaffirmed its long-term targets for growing revenue 8% per year or better and earnings per share by 12%-15% per year while increasing operating expenses by less than 3% per year, there are good reasons to be skeptical about its ability to hit those targets, according to The Wall Street Journal's "Heard on the Street" column. Competition from peer Visa (V) as well as big banks such as Citi (C) and Bank of America (BAC) may put pressure on AmExís margins and it is not safe to assume that the company will always fare as well on the Fed's stress tests as it just did, the report stated. Reference Link
07:13 EDTSHPGShire patent challenges only modest threat, says Jefferies
Subscribe for More Information
05:23 EDTSHPGShire reaches agreement with FDA on clear regulatory path for SHP465
Shire announces that it has reached an agreement with the FDA on a clear regulatory path for SHP465, an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder, or ADHD, in adults. Shire has agreed with the FDA to conduct a short-term efficacy and safety study in pediatric patients with ADHD. While Shire intends to pursue an adult indication, the FDA is requesting this additional pediatric data to better understand the potential effects of SHP465 on children with ADHD in the event of use in this population. The company anticipates the clinical trial's first patient, first visit to take place in August 2015, with study completion targeted by the last quarter of 2016. Shire then expects to submit to the FDA by 2Q17 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire's announcement on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission.
April 6, 2015
19:33 EDTCRegulators enter headquarters of Citibank Argentina, Reuters says
Subscribe for More Information
09:09 EDTSHPGShire says will defend patents 'vigorously' after Hayman petitions
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use